Post-approval studies (Phase 4)WithdrawnNCT02058875
What this trial is testing
Cardiovascular Risk Following Conversion to Full Dose Myfortic® and Neoral® Two-hour Post Level Monitoring
Who this might be right for
Cardiovascular DiseaseCardiovascular OutcomesKidney Transplant Recipients+1 more
University of Saskatchewan